Bayer and Aignostics Announce Strategic Collaboration in Precision Oncology

Bayer and Aignostics GmbH revealed a strategic alliance aimed at advancing precision oncology through artificial intelligence (AI)-fueled initiatives. This collaboration is set to harness Aignostics’ cutting-edge computational pathology and Bayer’s prowess in oncology therapy development. By integrating multimodal patient data with sophisticated AI and machine learning algorithms, the partnership seeks to expedite the discovery of new cancer targets and streamline clinical trials for oncology programs.

The multi-year collaboration will witness the creation of a novel platform for target identification, leveraging the strengths of both partners. Aignostics brings its proprietary technology and access to diverse patient cohorts, while Bayer contributes its deep drug development expertise. Together, they aim to improve patient identification, stratification, and selection processes, addressing significant hurdles in target discovery and disease heterogeneity.

Christian Rommel of Bayer highlighted the potential of integrating AI, machine learning, and pathology into drug development. Viktor Matyas, CEO of Aignostics, emphasized the collaboration’s potential to accelerate the development of better drugs for patients with unmet needs. As part of the agreement, Aignostics will receive an upfront payment, with additional success-based milestone payments and royalties for any therapies commercialized resulting from the collaboration.